Regulus Therapeutics Overview
Latest ROE for Regulus Therapeutics: -68.85% — see history and peer comparisons.
Get informed when a big investor buys or sells
+ Follow-68.85%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
The latest ROE for RGLS is -68.85%. That is below the Healthcare sector average of 29.33%. Investors often review this figure alongside Regulus Therapeutics's historical trend and sector peers before judging valuation or financial health.
Against Healthcare companies, RGLS currently prints -68.85% for ROE, while the sector average sits near 29.33%. That is roughly 334.7% below the sector mean. Large gaps often invite a closer look at Regulus Therapeutics's growth, margins, and balance sheet.
Return on Equity shows how effectively Regulus Therapeutics converts resources into returns. At -68.85%, RGLS may look efficient or underperforming depending on peer benchmarks and trend direction. Pair the percentage with revenue growth and leverage for a fuller health check.
After noting RGLS's ROE (-68.85%), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.
This page's peer comparison chart is the fastest way to stack Regulus Therapeutics's ROE against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.
